Skip to main content
Inventage Lab Inc. logo

Inventage Lab Inc. — Investor Relations & Filings

Ticker · 389470 ISIN · KR7389470006 KO Professional, scientific and technical activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2026-03-17 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 389470

About Inventage Lab Inc.

https://www.inventagelab.com/m/en/

Inventage Lab Inc. is a biopharmaceutical company specializing in the development of advanced Drug Delivery Systems (DDS). The company's foundation is its proprietary microfluidics-based platform technology, Laminar-FluiDigm™, which is applied to pharmaceutical research and manufacturing. Inventage Lab operates two primary platforms: IVL-DrugFluidic® for developing and producing microsphere-based long-acting injectables, and IVL-GeneFluidic® for the formulation and manufacturing of Lipid Nanoparticles (LNPs) for nucleic acid and gene therapies. The company's pipeline is focused on treating chronic and refractory diseases, with key programs targeting androgenic alopecia (male pattern baldness) and Alzheimer's disease. Other development areas include drug re-discovery for conditions like rheumatic arthritis and multiple sclerosis, and collaborative projects for HIV treatments and mRNA-based therapies.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) from Inventage Lab, specifically detailing a correction (정정신고) to a previous filing regarding a capital increase (유상증자결정). It contains detailed tables regarding conversion prices, share issuance terms, and board resolutions. Since this is a formal regulatory filing regarding capital structure changes and share issuance, it falls under the 'Share Issue/Capital Change' category.
2026-03-17 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Inventage Lab. It includes the meeting agenda, details on board activities, remuneration, and management reports (business overview). This type of document is standard for providing shareholders with necessary information prior to an Annual General Meeting (AGM) and is classified as Proxy Solicitation & Information Statement materials.
2026-03-17 Korean
증권발행결과(자율공시) (4CB)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Issuance Result' (증권 발행결과) filing from Inventage Lab. It details the completion of a private placement of convertible bonds (4th series), including the issuance amount and payment date. This falls under the category of capital and financing updates, specifically related to the issuance of debt instruments.
2026-03-16 Korean
증권발행결과(자율공시) (5BW)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Issuance Result' (증권 발행결과) filing from Inventage Lab. It details the final issuance of private placement bonds with warrants (BW). This falls under capital structure changes and financing activities, specifically categorized as a share/capital change announcement.
2026-03-16 Korean
증권발행결과(자율공시) (제3자배정유상증자-전환우선주)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a third-party allocation of convertible preferred shares). It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2026-03-16 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (Inventage Lab) announcing a significant change (over 30%) in revenue or profit structure compared to the previous fiscal year. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for listed companies to provide preliminary financial highlights before the final audit report is finalized. Since it provides key financial figures and reasons for the variance, it functions as an Earnings Release (ER) rather than a full annual report or a simple publication announcement. FY 2025
2026-03-16 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.